Aspire Biopharma closes $30 million acquisition of Dura Driver Control Systems

Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) announced on August 10, 2026 that it had completed its previously announced acquisition of Dura Driver Control Systems, a tier-one supplier specializing in automotive systems that facilitate electronic driver control and the migration toward vehicle electrification, safety, lightweighting, and sustainability.¹

Under the terms of the deal, Aspire acquired 100% of the issued and outstanding shares of DCS for approximately $30.0 million in cash, and DCS became a wholly owned subsidiary of the company.¹ To help fund the purchase, Aspire entered into a $22.5 million senior secured revolving credit facility, intending to use those borrowings along with cash on hand to cover the acquisition consideration.¹

According to the filing, for the six months ended June 30, 2026 and the twelve months ended December 31, 2025, DCS generated revenue of approximately $103.9 million and $209.5 million, respectively, along with Adjusted EBITDA of approximately $10.5 million and $22.3 million.¹ DCS operates 11 global manufacturing facilities across North America, Europe, and Asia,¹ and serves more than 50 customers with an average relationship longevity of 28 years among its top 10 OEM clients.¹

Separately, the filing discloses a working capital transaction: on August 6, 2026, the company issued convertible promissory notes to investors under a Convertible Promissory Note Purchase Agreement, in an aggregate principal amount of $3,750,000 for an aggregate purchase price of $3,000,000, reflecting a 20% original issue discount.¹ The notes carry a conversion price of $8.00 per share.¹ The company said the proceeds are intended to provide additional working capital and flexibility to pursue future growth opportunities.¹